CompARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

web_HPV_CompARE trial logo

Trial Overview and Summary

Chief Investigator: Professor Hisham Mehanna
Sponsor: University of Birmingham
Funders: Cancer Research UK, Clinical Trials Awards & Advisory Committee (CTAAC)
Disease Site: Head and Neck
Trial Type: Clinical Trial of Investigational Medicinal Products/ Radiotherapy/ Surgical Trial
Status: Open
UKCRN Study ID: (if applicable) 18621
Open to new sites? Yes
Recruitment start date: 6th July 2015
Anticipated Recruitment end date September 2023
CRCTU Trial Management Team: B Team
Trial E-mail Address: 

Trial Summary

The CompARE study has been set up to investigate which treatment is most effective for patients who have higher-risk oropharyngeal cancer. The purpose of this study is to consider using additional treatments in conjunction with standard chemoradiotherapy to increase cure rates of higher-risk oropharyngeal cancer. This will be done by adding surgery or immunotherapy or more chemotherapy or higher dose radiotherapy to the standard chemoradiotherapy. Immunotherapy is novel approach, which uses drugs that encourages the body's natural defence system, the immune system to attack cancer cells.

Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.

Trial Protocol

Please note: Clinical trial protocols are complex technical documents, which should only be used for the treatment of subjects taking part in the trial.  Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to  the CancerHelp website 

To view the Protocol and other trial related documents, please refer to the Investigators page.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.